PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-17

  1. 9,819 Posts.
    lightbulb Created with Sketch. 1249
    Safety, pain and function is our proposition

    ERT is DM but doesn't provide relief to this extraordinarily debilitating disease.

    So as expected PPS is not an aggressive DM drug like for instance Humira, that also has high correlating SAE


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.5¢
Change
0.005(2.17%)
Mkt cap ! $82.20M
Open High Low Value Volume
23.5¢ 23.5¢ 23.0¢ $85.35K 365.1K

Buyers (Bids)

No. Vol. Price($)
10 280011 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 44703 3
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.